Financing success: 20 million euros for Captain T Cell

Captain T Cell has successfully completed a major financing round, securing a total of EUR 20 million to advance its next-generation TCR-T therapies. The round was led by several new investors, with existing backers also increasing their commitments. TCR-T therapies are personalized immunotherapies in which a patient’s own T cells are genetically modified to recognize and attack cancer cells via their T cell receptors—a highly promising approach, especially for solid tumors. With this new funding, Captain T Cell can initiate its first Phase I clinical trial for its lead program CTC127 while simultaneously advancing its proprietary allogeneic “off-the-shelf” platform toward clinical trial readiness. This brings key milestones on the path toward benefiting patients significantly closer.

 

The round was led by Springboard Health Angels and Pluton Asset Holding AG, together with Sintra Ventures and Technologie Gründerfonds Sachsen, as well as existing investors i&i Bio, HIL-INVENT and Brandenburg Kapital.

Brandenburg Kapital GmbH has been supporting the company since 2023.

About Captain T Cell

Captain T Cell develops novel, highly potent T cell therapies for solid tumors that have so far been difficult to treat. The company generates next-generation TCR-T cells that remain active in the body for longer and can better withstand the hostile tumor microenvironment. In addition, Captain T Cell has built an allogeneic platform enabling future off-the-shelf treatments. The company, based in Schönefeld/Berlin, is supported by experienced European investors and was founded by a team of immuno-oncology experts. The underlying technologies were developed at the Max Delbrück Center for Molecular Medicine in Berlin. You can find further information at: www.brandenburg-kapital.de, www.captaintcell.com

 

 

Back